Patient engagement in Pharmacovigilance: determinants and evolution of reporting from 2011 to 2020 in France

Author:

Adopo D.1,Daynes P.2,Benkebil M.2,Debs A.2,Jonville-Berra AP3,Polard E.4,Micallef J.5,Maison P.2

Affiliation:

1. Universite Victor Segalen

2. Agence Nationale de Sécurité du Médicament et des Produits de Santé

3. Regional Pharmacovigilance Centre of Tours

4. Regional Pharmacovigilance Centre of Rennes

5. Regional Pharmacovigilance Centre Marseille Provence Corse

Abstract

Abstract Introduction: Because patients and patient organizations want to strengthen their role in the care pathway and drug evaluation and in order to improve pharmacovigilance activities, European competent authorities implemented regulations to allow direct reporting of adverse drug reactions related to medicinal products by patients in 2012. Objectives: Describe and study determinants and evolution of patient reporting activity in France to assess patient involvement in pharmacovigilance.Method: Using the French national pharmacovigilance database, univariate and multivariate analyses were performed to compare characteristics of patients and healthcare professionals (HCP) adverse drug reaction (ADR) report from 2011 to 2020. Then, we analyzed ADR report activities from patients according to regional demographics and economics characteristics.Results: We observed a significant and higher increase in ADR report over time from patient (r=0.89, p<0.001) compared to HCP reporting (r=0.27, p=0.002). Patient ADR report activities compared to HCP concerned more women (80% vs 55%, p<0.001), younger age classes (p<0.001) or reporting through web portal (83% vs 17%, p<0.001) and less serious events (26% vs 63%, p<0.001). In the principal component analysis, regional patient reporting activity was mainly related to socio-professional categories, age classes and densities of hospital beds and physicians. Conclusion: Our results confirm an increasing involvement of patients in ADR report activities. The determinants of patient reporting activities are not only related to drug and medical factors but also to social factors. Digital tools may also play a role in health democracy in pharmacovigilance.

Publisher

Research Square Platform LLC

Reference37 articles.

1. EMA. Legal framework: Pharmacovigilance [Internet]. European Medicines Agency. 2018 [cited 2022 Feb 4]. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/pharmacovigilance/legal-framework-pharmacovigilance

2. Rates of Spontaneous Reporting of Adverse Drug Reactions in France;Bégaud B;JAMA,2002

3. Section 2: Déclarations obligatoires. (Articles R5144-8 à R5144-11) - Légifrance [Internet]. [cited 2021 Mar 2]. Available from: https://www.legifrance.gouv.fr/codes/section_lc/LEGITEXT000006072665/LEGISCTA000006174544/1993-08-07/#LEGISCTA000006174544

4. Pharmacovigilance française: missions, organisation et perspectives;Vial T;Therapies.,2016

5. Décret n° 2011 – 655 du 10 juin 2011 relatif aux modalités de signalement par les patients ou les associations agréées de patients d’effets indésirables susceptibles d’être liés aux médicaments et produits mentionnés à l’article L. 5121-1 du code de la santé publique - Légifrance [Internet]. [cited 2021 Mar 2]. Available from: https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000024153599

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3